Aurobindo Pharma1790.60
+5.60 (+0.31%)

Aurobindo Pharma Share Price

1790.60+5.60 (+0.31%)
+55.83% past 1 Year

Corporate filings & documents

Announcements

Submission of Financial results for the Quarter and Half year ended September 30 2026.
1 day ago
Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1 2027.
1 day ago
Transfer of ownership of Auro Pharma LLC Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited Wholly Owned subsidiaries of the Company.
1 day ago
Approved the proposal of Merger of two wholly owned subsidiaries of the Company.
1 day ago
Intimation of record date for payment of interim dividend for FY 2026-2027.
1 day ago
Intimation of declaration of interim dividend for FY 2026-27.
1 day ago
Submission of Earnings Presentation on Q2 FY27 Financial Results.
1 day ago
Submission of Press Release on Q2 FY27 financial results
1 day ago
Submission of outcome of Board Meeting held on November 4 2026
1 day ago
Submission of newspaper publication.
1 day ago
Intimation of Earnings Call scheduled to be held on November 5 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026.
1 week ago
Intimation of Earnings Call scheduled to be held on November 5 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026.
1 week ago
Intimation of Earnings Call scheduled to be held on November 5 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026.
1 week ago
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 inter alia to consider and approve Intimation of Board Meeting scheduled to be held on November 4 2026 inter alia to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026 and Payment of Interim Dividend if any for the financial year 2026-27.
1 week ago
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 inter alia to consider and approve Intimation of Board Meeting scheduled to be held on November 4 2026 inter alia to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026 and Payment of Interim Dividend if any for the financial year 2026-27.
1 week ago
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 inter alia to consider and approve Intimation of Board Meeting scheduled to be held on November 4 2026 inter alia to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2026 and Payment of Interim Dividend if any for the financial year 2026-27.
1 week ago
Submission of Notice published in newspapers.
3 weeks ago
Submission of Notice published in newspapers.
3 weeks ago
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2026.
1 month ago
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2026.
1 month ago
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg 4 mg 6 mg 8 mg 10 mg and 12 mg.
1 month ago
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg 4 mg 6 mg 8 mg 10 mg and 12 mg.
1 month ago
Intimation of completion of acquisition.
1 month ago
Intimation of completion of acquisition.
1 month ago
Intimation of acquisition of a step down subsidiary in USA.
1 month ago
Intimation of acquisition of a step down subsidiary in USA.
1 month ago
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted a step down subsidiary of the Company.
1 month ago
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted a step down subsidiary of the Company.
1 month ago
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.
1 month ago
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.
1 month ago
Intimation of order passed by Appellate Joint Commissioner (ST) Malkajgiri Division Hyderabad Telangana.
1 month ago
Intimation of order passed by Appellate Joint Commissioner (ST) Malkajgiri Division Hyderabad Telangana.
1 month ago
Intimation of closure of trading window.
1 month ago
Intimation of closure of trading window.
1 month ago
Intimation of investor Analyst meet scheduled on 24.09.2026.
1 month ago
Intimation of investor Analyst meet scheduled on 24.09.2026.
1 month ago
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 month ago
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 month ago
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol 40 mcg and 80 mcg.
1 month ago
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol 40 mcg and 80 mcg.
1 month ago
Intimation of subscription of 10 000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited a step down subsidiary of the Company.
1 month ago
Intimation of subscription of 10 000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited a step down subsidiary of the Company.
1 month ago
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 month ago
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 month ago
Intimation of investor / analyst meet scheduled on 22.09.2026.
1 month ago
Intimation of investor / analyst meet scheduled on 22.09.2026.
1 month ago
Intimation of investor / analyst meet scheduled on 21.09.2026.
1 month ago
Intimation of investor / analyst meet scheduled on 21.09.2026.
1 month ago
Intimation of investor / analyst meet scheduled on 17.09.2026.
1 month ago
Intimation of investor / analyst meet scheduled on 17.09.2026.
1 month ago

Concalls & investor presentations

Nov 2026
Aug 2026
ConcallPresentation
Aug 2026
May 2026
ConcallPresentation
May 2026
Feb 2026
ConcallPresentation
Feb 2026
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
May 2025
Feb 2025
ConcallPresentation
Feb 2025
Nov 2024
ConcallPresentation
Nov 2024
Aug 2024
ConcallPresentation
Aug 2024
May 2024
ConcallPresentation
May 2024
Feb 2024
ConcallPresentation
Feb 2024
Nov 2023
ConcallPresentation
Nov 2023
Aug 2023
ConcallPresentation
Aug 2023
May 2023
ConcallPresentation
May 2023
Feb 2023
ConcallPresentation
Feb 2023
Nov 2022
ConcallPresentation
Nov 2022
Aug 2022
ConcallPresentation
Aug 2022
May 2022
ConcallPresentation
May 2022
Feb 2022
ConcallPresentation
Feb 2022
Jan 2022
Nov 2021
ConcallPresentation
Nov 2021
Aug 2021
ConcallPresentation
Aug 2021
Feb 2021
ConcallPresentation
Feb 2021
Nov 2020
ConcallPresentation
Nov 2020

Aurobindo Pharma Ltd Share Price Today

The Aurobindo Pharma Ltd share price today is ₹1667.2. During the trading session, the Aurobindo Pharma Ltd share price opened at ₹1677.9 and recorded an intraday high of ₹1700.7 and a low of ₹1654.2. Last closing price was ₹1672. Over the past 52 weeks, the Aurobindo Pharma Ltd share price has ranged between ₹1066.8 and ₹1740. The current Aurobindo Pharma Ltd stock price reflects real-time market activity based on executed trades on the exchange.